4.5 Article

Assessment of 17 clinically available renal biomarkers to predict acute kidney injury in critically ill patients

Journal

JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE
Volume 9, Issue 4, Pages 273-284

Publisher

SCIENDO
DOI: 10.2478/jtim-2021-0047

Keywords

acute kidney injury; biomarkers; critically ill adults; cystatin C

Funding

  1. Office of Talent Work Leading Group in Maoming [MaoRenCaiBan[2020]24]
  2. Guangzhou Science and Technology Program [201803010058]
  3. National Natural Science Foundation of China [81873950, 81671963]
  4. Major Program of Summit Project, Guangdong Province High-level Hospital Construction Project of Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences [DFJH2020028]
  5. Emergent Science and Technology Project for Prevention and Treatment of Novel Coronavirus Pneumonia [2020YJ01]
  6. High-level Hospital Construction Research Project of Maoming People's Hospital [zx2020017]
  7. Excellent Young Talents Project of Maoming People's Hospital [SY2021005]
  8. Science and Technology Planning Project of Guangdong Province, China [2016A020215129]
  9. High-level Hospital Construction Research Project of Maoming People's Hospital

Ask authors/readers for more resources

The study in the ICU patients found that serum cystatin C (CysC) had the best performance in predicting AKI and severe AKI. Combinations of CysC with N-acetyl-beta-d-glucosaminidase-to-creatinine ratio (NAG/Cr) or lactic acid (LAC) were effective for predicting AKI and severe AKI respectively. Additionally, CysC combined with clinical markers such as Acute Physiology and Chronic Health Evaluation (APACHE) II score or Multiple Organ Dysfunction Score (MODS) showed good predictive abilities for AKI and severe AKI.
Background: Systematic estimation of renal biomarkers in the intensive care unit (ICU) patients is lacking. Seventeen biomarkers were assessed to predict acute kidney injury (AKI) after admission to ICU. Materials and methods: A prospective, observational study was conducted in the general ICU of Guangdong Provincial People's Hospital. Seventeen serum or urine biomarkers were studied for their abilities alone or in combination for predicting AKI and severe AKI. Results: Of 1498 patients, 376 (25.1%) developed AKI. Serum cystatin C (CysC) showed the best performance for predicting both AKI (area under the receiver operator characteristic curve [AUC] = 0.785, mean square error [MSE] = 0.118) and severe AKI (AUC = 0.883, MSE = 0.06). Regarding biomarkers combinations, CysC plus N-acetyl-beta-d-glucosaminidase-to-creatinine ratio (NAG/Cr) was the best for predicting AKI (AUC = 0.856, MSE = 0.21). At the same time, CysC plus lactic acid (LAC) performed the best for predicting severe AKI (AUC = 0.907, MSE = 0.058). Regarding combinations of biomarkers and clinical markers, CysC plus Acute Physiology and Chronic Health Evaluation (APACHE) II score showed the best performance for predicting AKI (AUC = 0.868, MSE = 0.407). In contrast, CysC plus Multiple Organ Dysfunction Score (MODS) had the highest predictive ability for severe AKI (AUC = 0.912, MSE = 0.488). Conclusion: Apart from CysC, the combination of most clinically available biomarkers or clinical markers does not significantly improve the forecasting ability, and the cost-benefit ratio is not economical.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available